355 related articles for article (PubMed ID: 25587648)
1. Cardiovascular disease in adult survivors of childhood cancer.
Lipshultz SE; Franco VI; Miller TL; Colan SD; Sallan SE
Annu Rev Med; 2015; 66():161-76. PubMed ID: 25587648
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular disease in survivors of childhood cancer.
Bansal N; Amdani SM; Hutchins KK; Lipshultz SE
Curr Opin Pediatr; 2018 Oct; 30(5):628-638. PubMed ID: 30124579
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-induced cardiotoxicity in children.
Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
[TBL] [Abstract][Full Text] [Related]
4. Cardiac complications in childhood cancer survivors treated with anthracyclines.
Franco VI; Lipshultz SE
Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
[TBL] [Abstract][Full Text] [Related]
5. Prevention of cardiotoxicity among survivors of childhood cancer.
Hutchins KK; Siddeek H; Franco VI; Lipshultz SE
Br J Clin Pharmacol; 2017 Mar; 83(3):455-465. PubMed ID: 27591829
[TBL] [Abstract][Full Text] [Related]
6. Treatment-related cardiotoxicity in survivors of childhood cancer.
Lipshultz SE; Cochran TR; Franco VI; Miller TL
Nat Rev Clin Oncol; 2013 Dec; 10(12):697-710. PubMed ID: 24165948
[TBL] [Abstract][Full Text] [Related]
7. Minimizing cardiac toxicity in children with acute myeloid leukemia.
Narayan HK; Getz KD; Leger KJ
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):368-375. PubMed ID: 34889355
[TBL] [Abstract][Full Text] [Related]
8. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.
de Baat EC; Mulder RL; Armenian S; Feijen EA; Grotenhuis H; Hudson MM; Mavinkurve-Groothuis AM; Kremer LC; van Dalen EC
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD014638. PubMed ID: 36162822
[TBL] [Abstract][Full Text] [Related]
9. Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.
Rygiel K
Indian J Pharmacol; 2016; 48(5):490-497. PubMed ID: 27721532
[TBL] [Abstract][Full Text] [Related]
10. Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
de Baat EC; van Dalen EC; Mulder RL; Hudson MM; Ehrhardt MJ; Engels FK; Feijen EAM; Grotenhuis HB; Leerink JM; Kapusta L; Kaspers GJL; Merkx R; Mertens L; Skinner R; Tissing WJE; de Vathaire F; Nathan PC; Kremer LCM; Mavinkurve-Groothuis AMC; Armenian S
Lancet Child Adolesc Health; 2022 Dec; 6(12):885-894. PubMed ID: 36174614
[TBL] [Abstract][Full Text] [Related]
11. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity and cardioprotection in childhood cancer.
Lipshultz SE; Sambatakos P; Maguire M; Karnik R; Ross SW; Franco VI; Miller TL
Acta Haematol; 2014; 132(3-4):391-9. PubMed ID: 25228565
[TBL] [Abstract][Full Text] [Related]
13. Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.
Lipshultz SE; Diamond MB; Franco VI; Aggarwal S; Leger K; Santos MV; Sallan SE; Chow EJ
Paediatr Drugs; 2014 Oct; 16(5):373-89. PubMed ID: 25134924
[TBL] [Abstract][Full Text] [Related]
14. Aerobic exercise in anthracycline-induced cardiotoxicity: a systematic review of current evidence and future directions.
Chen JJ; Wu PT; Middlekauff HR; Nguyen KL
Am J Physiol Heart Circ Physiol; 2017 Feb; 312(2):H213-H222. PubMed ID: 27923793
[TBL] [Abstract][Full Text] [Related]
15. Educational paper: decreasing the burden of cardiovascular disease in childhood cancer survivors: an update for the pediatrician.
Dillenburg RF; Nathan P; Mertens L
Eur J Pediatr; 2013 Sep; 172(9):1149-60. PubMed ID: 23361962
[TBL] [Abstract][Full Text] [Related]
16. Strategies to Prevent Cardiotoxicity.
Graffagnino J; Kondapalli L; Arora G; Hawi R; Lenneman CG
Curr Treat Options Oncol; 2020 Apr; 21(4):32. PubMed ID: 32270293
[TBL] [Abstract][Full Text] [Related]
17. Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors.
Lipshultz SE; Anderson LM; Miller TL; Gerschenson M; Stevenson KE; Neuberg DS; Franco VI; LiButti DE; Silverman LB; Vrooman LM; Sallan SE;
Cancer; 2016 Mar; 122(6):946-53. PubMed ID: 26762648
[TBL] [Abstract][Full Text] [Related]
18. Cardiac Outcomes in Survivors of Pediatric and Adult Cancers.
Nathan PC; Amir E; Abdel-Qadir H
Can J Cardiol; 2016 Jul; 32(7):871-80. PubMed ID: 27179545
[TBL] [Abstract][Full Text] [Related]
19. Comment on: Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane.
Mavinkurve-Groothuis AMC; de Baat EC; Feijen EAM; Kremer LCM; Armenian SH; Mulder RL; van Dalen EC
Pediatr Blood Cancer; 2023 Oct; 70(10):e30604. PubMed ID: 37505793
[No Abstract] [Full Text] [Related]
20. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
